REGN vs. NVO
Compare and contrast key facts about Regeneron Pharmaceuticals, Inc. (REGN) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: REGN or NVO.
Correlation
The correlation between REGN and NVO is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
REGN vs. NVO - Performance Comparison
Key characteristics
REGN:
-0.75
NVO:
0.15
REGN:
-0.90
NVO:
0.44
REGN:
0.88
NVO:
1.05
REGN:
-0.40
NVO:
0.14
REGN:
-1.09
NVO:
0.35
REGN:
15.08%
NVO:
12.98%
REGN:
21.92%
NVO:
30.53%
REGN:
-91.81%
NVO:
-71.30%
REGN:
-41.50%
NVO:
-29.32%
Fundamentals
REGN:
$81.32B
NVO:
$486.49B
REGN:
$40.40
NVO:
$2.99
REGN:
18.32
NVO:
36.12
REGN:
1.10
NVO:
1.61
REGN:
$13.85B
NVO:
$270.58B
REGN:
$11.69B
NVO:
$229.07B
REGN:
$4.83B
NVO:
$135.97B
Returns By Period
In the year-to-date period, REGN achieves a -19.96% return, which is significantly lower than NVO's 1.09% return. Over the past 10 years, REGN has underperformed NVO with an annualized return of 5.47%, while NVO has yielded a comparatively higher 19.11% annualized return.
REGN
-19.96%
-5.59%
-32.69%
-16.49%
13.38%
5.47%
NVO
1.09%
0.79%
-26.36%
3.23%
31.11%
19.11%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
REGN vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
REGN vs. NVO - Dividend Comparison
REGN has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 1.40%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 1.40% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% | 1.72% |
Drawdowns
REGN vs. NVO - Drawdown Comparison
The maximum REGN drawdown since its inception was -91.81%, which is greater than NVO's maximum drawdown of -71.30%. Use the drawdown chart below to compare losses from any high point for REGN and NVO. For additional features, visit the drawdowns tool.
Volatility
REGN vs. NVO - Volatility Comparison
Regeneron Pharmaceuticals, Inc. (REGN) and Novo Nordisk A/S (NVO) have volatilities of 7.59% and 7.24%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Financials
REGN vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Regeneron Pharmaceuticals, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities